Answers are grounded in this paper and cite their sources.
Toxicity, adherence problems, and virological failure may limit treatment by protease inhibitor-containing regimens at standard doses. Addition of low-dose ritonavir results in a high plasma concentration of coadministered protease inhibitor resulting in decreased pill burden, a reduction in the number of doses, fewer food and/or fluid restrictions, and a higher rate of virological suppression. These effects are due to improved pharmacokinetics of coadministered protease inhibitors.
No takes yet. Share an insight, caveat, or question.
Motwani et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: